key: cord-1000192-nb5dx89t authors: Defreyne, Luc title: Interventional radiology for liver diseases date: 2020-10-03 journal: Eur Radiol DOI: 10.1007/s00330-020-07356-w sha: f4d7eec22f79059adeb18f546e5b7aa2bc1df2dd doc_id: 1000192 cord_uid: nb5dx89t nan Over the past thirty years interventional radiology of the liver has evolved tremendously. Established as portal vein decompression and tumor treatment, IR technology advanced continuously. Covered ePTFE stents significantly increased TIPS patency and ascites control [1, 2]. ePTFE-covered stents were tested in percutaneous palliation of biliary malignancies to prevent tumor ingrowth and increase patency. Randomized controlled trials (RCT) endorsed covered stents in extrahepatic bile duct malignancies [3] . For intrahepatic biliary malignancies, ePTFE-covered stents worked but failed to fulfill their promise: sludge formation on the inner coating impedes longer patency times [4] . Long-term patency of stents becomes a major issue, as progress in medical treatment offers longer live expectancy for patients with, i.e., portal hypertension, Budd-Chiari disease, biliary strictures, or malignancies. Research projects on drug-eluting stents and radioactive or resorbable stents are ongoing [5, 6] . Although metallic stents have been put aside in benign biliary strictures in favor of repeat balloon dilatation, preliminary results with a biodegradable stent are promising [7, 8] . Conventional chemoembolization (cTACE) and radiofrequency ablation (RFA) were embedded in the Barcelona Classification of Liver Cancer (BCLC), remaining unchallenged as level I treatments for intermediate and early HCC for almost twenty years [9-13]. However, cTACE suffers from drug and dose variation as well as technical permutations. The drug-eluting beads (DEB-TACE, Boston Scientific) installed standardization of chemoembolization, proving efficacy but not yet superiority over cTACE [14] [15] [16] . Because of a lower post-embolization toxicity, DEB-TACE research was continued with emerging of eluting microspheres manufactured from polyvinyl alcohol (CalliSpheres, Jiangsu Hengrui), expanding trisacryl/gelatin (HepaSphere or QuadraSphere, Merit Medical), polyethylene glycol (LifePearl, Terumo), and hydrogel with polyzene coating (Tandem, Varian). All DEB-TACE beads are nonresorbable agents, permanently blocking tumor supply at different levels according to bead sizes (from 500 to 40 μ) [17-20]. As tumor response did not quite differ, the question remains whether the eluting chemotherapeutic or the embolic particulate dominates the anti-tumor effect. Interestingly, degradable starch microspheres combined with a chemotherapeutic are finding their way into clinical practice, even in advanced HCC [21] . Biodegradable microspheres are captivating with a range of "biogel" materials now under investigation [22] . First in queue for clinical testing are combined degradable and drug-eluting beads (BioPearl, Terumo), which might provide more insight into the anti-tumoral mode of action. Innovations in bead delivery such as radiopaque beads (DC Bead LUMI), beads in combination with Lipiodol or steerable microcatheters (swingNINA®, Merit), anti-reflux mechanism (Surefire, TriSalus Life Science; SeQure, Guerbet), or underpressure inducing balloon microcatheter (Occlusafe, Terumo) increase safety but impact on tumor response is still investigational [23] [24] [25] [26] . Intriguing for the future are composite microbeads, made of magnetic nanoparticles and polymeric matrix microspheres that may induce tumor ablation effects upon application of alternating magnetic field [27] . Despite the huge experience with Y90 in HCC, modern transarterial radioembolization (TARE) still struggles to enter the BCLC classification [ For colorectal liver metastasis (mCRC), TARE was a great hope to grant patients a "chemo-holiday" and eventually improve outcome. However, there is no evidence that chemotherapy with resin Y90 TARE improves OS or quality of life [40, 41] . Whether the glass Y90, with less particles but higher activity per bead, will turn the tables for TARE in second line for mCRC will be revealed soon [42] . Established IR solutions are challenged by innovations in endoscopy (i.e., percutaneous versus echo-endo biliary stenting), surgery (i.e., portal vein embolization versus ALLPS), or even systemic treatments [43] . Competition, research, and collaboration should keep IR in the front line for delivery of future pharmacology such as radio-and nanoparticles or modified virus or other immunotherapy. Portal and hepatic vein research, whether for implantation of I125 seeds in tumorous occlusion, as entry for autotransplantation of islet cell, as part of percutaneous hepatic perfusion (chemosaturation) or to increase safety of hepatectomy should receive full attention [44] [45] [46] [47] . Extending angiography by cone beam or hybrid angio-CT systems with image fusion, combined with high frequency jet ventilation should keep IR in pole position for efficient and safe tumor ablation [48] [49] [50] [51] . Cost-effectiveness studies combining quality of life and/or treatment outcome should increase acceptance of IR, even if "willingness to pay" is heavily dependent on one country's health policy [52] [53] [54] . Finally, IR should contemplate not only on trial protocols comparing locoregional treatments but also disclose and publish existing data to avoid futile research and underreporting [55] . Funding The authors state that this work has not received any funding. Guarantor The scientific guarantor of this publication is Luc Defreyne. The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. Statistics and biometry No complex statistical methods were necessary for this paper. Informed consent Written informed consent was not required for this study because it is an Editorial comment. Ethical approval Institutional Review Board approval was not required because it is an Editorial comment. 2020) 125 I irradiation stent for hepatocellular carcinoma with main portal vein tumor thrombosis: a systematic review The role of total pancreatectomy with islet autotransplantation in the treatment of chronic pancreatitis: a report from the international consensus guidelines in chronic pancreatitis Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function Use of high-frequency jet ventilation for percutaneous tumor ablation Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival Percutaneous thermal ablation of subcapsular hepatocellular carcinomas: influence of tumor-surface contact and protrusion on therapeutic efficacy and safety Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK Results of trials assessing transarterial chemoembolization for treating hepatocellular carcinoma are critically underreported Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations